search
Back to results

A Safety Study of ABI-007 for In-Stent Restenosis

Primary Purpose

Angina Pectoris, Coronary Artery Disease

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Paclitaxel Nanoparticle Albumin Bound
Paclitaxel Nanoparticle Albumin Bound
Paclitaxel Nanoparticle Albumin Bound
Sponsored by
Celgene
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Angina Pectoris focused on measuring In-Stent Restenosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries Diagnosis of angina pectoris At least 18 yrs old If female, negative pregnancy test, non-lactating, and agree to utilize methods to prevent pregnancy No previous treatment for In-Stent Restenosis Patient agrees to comply with follow-up evaluation Informed Consent obtained Target vessel at least 3 mm diameter Total stent less than 25 mm Left ventricular ejection fraction at least 30% No more than a single stent will be used per lesion No more than one stented lesion per vessel with the exception that 2 lesions in a single vessel are allowable if covered by less than 25 mm of continuous stent By Intravascular Ultrasound (IVUS), stent is fully opposed and has a minimum diameter of 3 mm or an in-stent luminal area of at least 7 mm2 TIMI 3 coronary flow post-stenting No angiographic evidence of thrombus post-stenting General Exclusion Criteria: More than two lesions treated with Percutaneous Coronary Intervention (PCI) or it is anticipated that additional lesions will require treatment within two months Previous PCI within preceding three months Previous participation in another study within 30 days Life expectancy less than 12 months Factors making follow-up difficult Intended surgical intervention within 6 months of study participation Investigator decision that patient is unsuitable Recipient of heart transplant Q wave or non-Q wave Myocardial Infarction (MI) with documented total CK greater than 2X normal upper limits within the preceding 24 hrs and the CK and CK-MB enzymes remain above normal at the time of the procedure Cardiogenic shock May refuse blood transfusion Gastro-intestinal bleeding within past 3 months Platelet count less than 100,000 cells/mm3 Impaired renal function Known allergies/hypersensitivity to aspirin, clopidogrel bisulfate, and/or stainless steel Exclusion Criteria Related to Angioplasty: Intervention for another lesion occurred within 90 days or is planned for within 60 days after the index procedure Stent is located in a coronary bypass Unprotected left main disease with greater than 50% stenosis Lost a side branch greater than 2 mm during stenting procedure Angiographic evidence of thrombus post-stenting Prior stent within 5 mm of target lesion Left ventricular ejection fraction less than 30% Greater than 50% stenosis proximal or distal to target lesion Malposition, dissection, or unmasking of a significant narrowing in the inflow or outflow area of the implanted stent Patient has received a drug coated stent as part of this procedure Exclusion Criteria Related to ABI-007: Absolute neutrophil count is less than 1500 cells/mm3 Platelet count is less than 100,000 cells/mm3 Bilirubin greater than 1.5 mg/dl or SGOT and SGPT greater than 2.5X upper limit of normal or alkaline phosphatase greater than 2.5X upper limit of normal Creatinine greater than 2.5X upper limit normal Pre-existing peripheral neuropathy of NCI toxicity Criteria Scale of Grade greater than 1 Immunosuppressed or has HIV or AIDS Hypersensitivity to Taxane

Sites / Locations

  • Abraxis BioScience, Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

1

2

Arm Description

35mg/m^2 infusion time is 3.5 minutes

2 doses of 35mg.m^2 with the second dose given 2 months later

Outcomes

Primary Outcome Measures

Incidence of treatment-emergent adverse events and serious adverse events.
Major Adverse Cardiac Events at 2 months following the stent procedure.
Safety and tolerability for ABI-007

Secondary Outcome Measures

Evaluation of restenosis at 6 months.

Full Information

First Posted
October 4, 2004
Last Updated
November 14, 2019
Sponsor
Celgene
search

1. Study Identification

Unique Protocol Identification Number
NCT00093223
Brief Title
A Safety Study of ABI-007 for In-Stent Restenosis
Official Title
A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
September 1, 2001 (Actual)
Primary Completion Date
December 1, 2007 (Actual)
Study Completion Date
December 1, 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Celgene

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries. The purpose of the trial is to determine the appropriate dose of the new medicine for future trials and to evaluate the incidence of treatment-emergent adverse events and serious adverse events.
Detailed Description
See inclusion/exclusion criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Angina Pectoris, Coronary Artery Disease
Keywords
In-Stent Restenosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
76 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
35mg/m^2 infusion time is 3.5 minutes
Arm Title
2
Arm Type
Experimental
Arm Description
2 doses of 35mg.m^2 with the second dose given 2 months later
Intervention Type
Drug
Intervention Name(s)
Paclitaxel Nanoparticle Albumin Bound
Intervention Description
Single or duel doses of 35mg/m^2 ABI-007, administered IV, administered after placement of denovo stent(s).
Intervention Type
Drug
Intervention Name(s)
Paclitaxel Nanoparticle Albumin Bound
Intervention Type
Drug
Intervention Name(s)
Paclitaxel Nanoparticle Albumin Bound
Intervention Description
35mg/35 infusion time is 3.5 minutes
Primary Outcome Measure Information:
Title
Incidence of treatment-emergent adverse events and serious adverse events.
Time Frame
6 months
Title
Major Adverse Cardiac Events at 2 months following the stent procedure.
Time Frame
2 months
Title
Safety and tolerability for ABI-007
Time Frame
2 Years
Secondary Outcome Measure Information:
Title
Evaluation of restenosis at 6 months.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries Diagnosis of angina pectoris At least 18 yrs old If female, negative pregnancy test, non-lactating, and agree to utilize methods to prevent pregnancy No previous treatment for In-Stent Restenosis Patient agrees to comply with follow-up evaluation Informed Consent obtained Target vessel at least 3 mm diameter Total stent less than 25 mm Left ventricular ejection fraction at least 30% No more than a single stent will be used per lesion No more than one stented lesion per vessel with the exception that 2 lesions in a single vessel are allowable if covered by less than 25 mm of continuous stent By Intravascular Ultrasound (IVUS), stent is fully opposed and has a minimum diameter of 3 mm or an in-stent luminal area of at least 7 mm2 TIMI 3 coronary flow post-stenting No angiographic evidence of thrombus post-stenting General Exclusion Criteria: More than two lesions treated with Percutaneous Coronary Intervention (PCI) or it is anticipated that additional lesions will require treatment within two months Previous PCI within preceding three months Previous participation in another study within 30 days Life expectancy less than 12 months Factors making follow-up difficult Intended surgical intervention within 6 months of study participation Investigator decision that patient is unsuitable Recipient of heart transplant Q wave or non-Q wave Myocardial Infarction (MI) with documented total CK greater than 2X normal upper limits within the preceding 24 hrs and the CK and CK-MB enzymes remain above normal at the time of the procedure Cardiogenic shock May refuse blood transfusion Gastro-intestinal bleeding within past 3 months Platelet count less than 100,000 cells/mm3 Impaired renal function Known allergies/hypersensitivity to aspirin, clopidogrel bisulfate, and/or stainless steel Exclusion Criteria Related to Angioplasty: Intervention for another lesion occurred within 90 days or is planned for within 60 days after the index procedure Stent is located in a coronary bypass Unprotected left main disease with greater than 50% stenosis Lost a side branch greater than 2 mm during stenting procedure Angiographic evidence of thrombus post-stenting Prior stent within 5 mm of target lesion Left ventricular ejection fraction less than 30% Greater than 50% stenosis proximal or distal to target lesion Malposition, dissection, or unmasking of a significant narrowing in the inflow or outflow area of the implanted stent Patient has received a drug coated stent as part of this procedure Exclusion Criteria Related to ABI-007: Absolute neutrophil count is less than 1500 cells/mm3 Platelet count is less than 100,000 cells/mm3 Bilirubin greater than 1.5 mg/dl or SGOT and SGPT greater than 2.5X upper limit of normal or alkaline phosphatase greater than 2.5X upper limit of normal Creatinine greater than 2.5X upper limit normal Pre-existing peripheral neuropathy of NCI toxicity Criteria Scale of Grade greater than 1 Immunosuppressed or has HIV or AIDS Hypersensitivity to Taxane
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
José Iglesias, MD
Organizational Affiliation
Celgene Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Abraxis BioScience, Inc.
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27703
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Safety Study of ABI-007 for In-Stent Restenosis

We'll reach out to this number within 24 hrs